Philippe L. Bédard

22.9k total citations · 5 hit papers
347 papers, 9.7k citations indexed

About

Philippe L. Bédard is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philippe L. Bédard has authored 347 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Oncology, 127 papers in Cancer Research and 115 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philippe L. Bédard's work include Cancer Genomics and Diagnostics (96 papers), Testicular diseases and treatments (55 papers) and Cancer Immunotherapy and Biomarkers (55 papers). Philippe L. Bédard is often cited by papers focused on Cancer Genomics and Diagnostics (96 papers), Testicular diseases and treatments (55 papers) and Cancer Immunotherapy and Biomarkers (55 papers). Philippe L. Bédard collaborates with scholars based in Canada, United States and Spain. Philippe L. Bédard's co-authors include Lillian L. Siu, Aaron R. Hansen, Mark J. Ratain, Martine Piccart, David M. Hyman, Matthew S. Davids, Ben Tran, Janet Dancey, Eitan Amir and Nicole Onetto and has published in prestigious journals such as Nature, Cell and The Lancet.

In The Last Decade

Philippe L. Bédard

329 papers receiving 9.6k citations

Hit Papers

Tumour heterogeneity in the clinic 2013 2026 2017 2021 2013 2020 2018 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumour heterogeneity in the clinic
    2013 897 citations Philippe L. Bédard, Aaron R. Hansen et al. profile →
  2. Small molecules, big impact: 20 years of targeted therapy in oncology
    2020 416 citations Philippe L. Bédard, Lillian L. Siu et al. profile →
  3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    2018 391 citations Philippe L. Bédard, Lajos Pusztai et al. Annals of Oncology profile →
  4. Novel patterns of response under immunotherapy
    2019 354 citations Philippe L. Bédard et al. Annals of Oncology profile →
  5. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
    2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe L. Bédard Canada 50 4.6k 3.2k 2.9k 2.3k 1.2k 347 9.7k
Marcia S. Brose United States 44 4.5k 1.0× 3.6k 1.1× 1.4k 0.5× 2.1k 0.9× 1.1k 0.9× 187 11.5k
Alberto Ocaña Spain 51 7.3k 1.6× 3.8k 1.2× 2.5k 0.9× 2.5k 1.1× 950 0.8× 302 12.3k
George Somlo United States 51 6.1k 1.3× 4.7k 1.5× 3.8k 1.3× 1.8k 0.8× 767 0.7× 279 12.2k
Nuhad K. Ibrahim United States 42 6.3k 1.4× 2.8k 0.9× 3.9k 1.4× 1.8k 0.8× 612 0.5× 145 10.0k
Vivek Subbiah United States 54 6.0k 1.3× 3.7k 1.2× 3.1k 1.1× 4.6k 2.0× 1.7k 1.4× 599 12.2k
Sheila E. Taube United States 21 4.5k 1.0× 3.2k 1.0× 3.5k 1.2× 1.8k 0.8× 882 0.8× 38 9.0k
Stefan Sleijfer Netherlands 61 7.1k 1.6× 4.2k 1.3× 3.5k 1.2× 4.7k 2.0× 1.0k 0.9× 379 13.6k
Anthony Gonçalvès France 45 6.2k 1.3× 2.8k 0.9× 2.3k 0.8× 3.0k 1.3× 535 0.5× 318 9.5k
Eliezer M. Van Allen United States 51 4.7k 1.0× 5.2k 1.6× 3.2k 1.1× 3.9k 1.7× 977 0.8× 233 11.5k
Massimo Gion Italy 30 3.8k 0.8× 3.2k 1.0× 2.6k 0.9× 1.5k 0.6× 830 0.7× 139 8.1k

Countries citing papers authored by Philippe L. Bédard

Since Specialization
Citations

This map shows the geographic impact of Philippe L. Bédard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe L. Bédard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe L. Bédard more than expected).

Fields of papers citing papers by Philippe L. Bédard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe L. Bédard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe L. Bédard. The network helps show where Philippe L. Bédard may publish in the future.

Co-authorship network of co-authors of Philippe L. Bédard

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe L. Bédard. A scholar is included among the top collaborators of Philippe L. Bédard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe L. Bédard. Philippe L. Bédard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rose, April A. N., Ian King, Tong Zhang, et al.. (2024). Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.. Journal of Clinical Oncology. 42(16_suppl). 3104–3104. 2 indexed citations
2.
3.
Kehl, Kenneth L., Jessica A. Lavery, Samantha Brown, et al.. (2024). Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set. JCO Precision Oncology. 8(8). e2300489–e2300489. 1 indexed citations
4.
Cavalcante, Ludimila, Lillian L. Siu, John Toso, et al.. (2023). 375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors. Annals of Oncology. 34. S333–S333. 1 indexed citations
5.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554. 9 indexed citations
6.
Tabernero, Josep, Philippe L. Bédard, Yung‐Jue Bang, et al.. (2023). Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Research Communications. 3(8). 1662–1671. 9 indexed citations
7.
Raphael, Michael J., Sumit Gupta, Xuejiao Wei, et al.. (2021). Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. Journal of Clinical Oncology. 39(7). 779–786. 20 indexed citations
8.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629. 257 indexed citations breakdown →
9.
Elliott, Mitchell J., Marguerite Ennis, Kathleen I. Pritchard, et al.. (2020). Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. npj Breast Cancer. 6(1). 22–22. 9 indexed citations
10.
Ribnikar, Domen, Igor Stukalin, Philippe L. Bédard, et al.. (2020). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology. 28(1). 107–114. 9 indexed citations
11.
Chen, Lina, Lisa Wang, Anna Spreafico, et al.. (2019). Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology. 85(2). 469–472. 1 indexed citations
12.
Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. Clinical Cancer Research. 24(18). 4380–4387. 57 indexed citations
13.
Drögemöller, Britt I., Beth Brooks, Jose Gerard Monzon, et al.. (2018). Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clinical Cancer Research. 24(8). 1866–1871. 28 indexed citations
14.
Lewin, Jeremy, Laleh Soltan Ghoraie, Philippe L. Bédard, et al.. (2018). Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. British Journal of Urology. 122(5). 814–822. 8 indexed citations
15.
Leão, Ricardo, Madhur Nayan, Nahid Punjani, et al.. (2018). A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus. 4(6). 995–1001. 22 indexed citations
16.
Papadopoulos, Kyriakos P., Robin Kate Kelley, Anthony W. Tolcher, et al.. (2015). A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(6). 1348–1355. 59 indexed citations
17.
Tan, David S.P., Philippe L. Bédard, John Kuruvilla, Lillian L. Siu, & Albiruni Ryan Abdul Razak. (2014). Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy. Cancer Discovery. 4(5). 527–537. 75 indexed citations
18.
Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations
19.
Hatzis, Christos, Philippe L. Bédard, Nicolai J. Birkbak, et al.. (2014). Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?. Cancer Research. 74(15). 4016–4023. 67 indexed citations
20.
Azim, Hatem A., Stefan Michiels, Philippe L. Bédard, et al.. (2012). Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. Clinical Cancer Research. 18(5). 1341–1351. 278 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcia S. Brose Breakdown of academic impact, for papers by Alberto Ocaña Breakdown of academic impact, for papers by George Somlo Breakdown of academic impact, for papers by Nuhad K. Ibrahim Breakdown of academic impact, for papers by Vivek Subbiah Breakdown of academic impact, for papers by Sheila E. Taube Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Anthony Gonçalvès Breakdown of academic impact, for papers by Eliezer M. Van Allen Breakdown of academic impact, for papers by Massimo Gion
Rankless by CCL
2026